目的 考察硫酸软骨素注射剂的质量现状及存在问题,选取涉及产品有效性和安全性的关键质控项目进行研究,进一步完善质量标准。方法 采用现行标准对抽验样品进行法定检验,查阅国内外标准及文献,赴生产企业实地调研,采用酶解液相色谱法、激光光散射法、反相色谱法及体积排阻色谱法等方法对该品种的质量状况进行全面评价。结果 2016年硫酸软骨素注射剂国家评价性抽验结果表明,虽然法定标准检验结果均符合规定,但采用新的含量测定方法检测,多批次产品含量测定结果超出标准规定上限;标准中缺乏对相对分子质量的控制;二糖组成的测定结果提示,部分原料存在混入其他来源原料的风险;硫酸软骨素的抗凝血作用初步研究结果表明,不同来源的硫酸软骨素均具有抗凝血作用,鲨鱼来源的硫酸软骨素抗凝血作用最强。结论 我国硫酸软骨素注射剂含量测定、相对分子质量与相对分子质量分布等检验项目亟待完善提高。
Abstract
OBJECTIVE To investigate the quality status and problems of chondroitin sulfate injections and select the critical quality control items concerning the efficacy and safety to study in order to improve the quality standards. METHODS The statutory methods were adopted to test the samples. Many testing methods were established or improved on the basis of domestic and international standards and literature review and field research,including enzymatic HPLC,multiangle laser light scatter (MALLS),reverse phase chromatography,size exclusion chromatography, etc. RESULTS The national evaluation test in 2016 showed that all 41 batches of the samples met the requirements of current specifications. Exploratory studies showed that the assay results of the samples from some companies were obviously above the upper limit. The injection standard lacked control of molecular weight and molecular weight distribution. The disaccharide composition analysis suggested that in some bulk drug there was the risk of other origins of chondroitin sulfate sodium incorporation into the API. The study on the anticoagulatory effect of chondroitin sulfate sodium showed that chondroitin sulfate sodium from different origins had the action of anticoagulation. Chondroitin sulfate sodium from shark source had the most potensive anticoagulation effect. CONCLUSION Some items in the quality specification of chondroitin sulfate sodium injections are infeasible,including assay and molecular weight and molecular weight distribution need to be improved.
关键词
硫酸软骨素 /
硫酸软骨素钠 /
质量标准 /
质量评价 /
评价性抽验
{{custom_keyword}} /
Key words
chondroitin sulfate /
chondroitin sulfate sodium /
quality specification /
quality evaluation /
evaluative testing
{{custom_keyword}} /
中图分类号：
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MARTIN M S, VAN SELL S, DANTER J. Glucosamine and chondroitin: an appropriate adjunct treatment of symptomatic osteoarthri-tis of the knee. Orthop Nurs, 2012, 31(3):160-166.
[2] YOUSRY H, HAMMAD H R, MAGID M M. Clinical and biochemical study of the comparative efficacy of topical versus oral glucosamine/chondroitin sulfate on osteoarthritis of the knee. Egypt Rheumatologist, 2015, 37(2):85-91.
[3] Ch.P(2010). Vol Ⅱ( 中国药典 2010 年版. 二部) . 2010: 984-986.
[4] Ch.P( 2015). Vol Ⅱ( 中国药典 2015 年版. 二部) . 2015: 1340-1341.
[5] REN L P,YU H Z,SONG Y J, et al. Enzymolysis-HPLC determination of the content of chondroitin sulfate sodium. Chin J Pharm Anal(药物分析杂志), 2012, 32(7):1246-1248.
[6] CHEN S,XUE C,YIN L A, et al. Comparison of structures and anti-coagulant activities of fucosylated chondroitin sulfates from different sea cucumbers. Carbohydr Polym, 2011, 83(2):688-696.
[7] VOLPI N.Disaccharide mapping of chondroitin sulfate of different origins by high-performance capillary electrophoresis and high-performance liquid chromatography. Carbohydr Polym, 2004, 55(3):273-281.
[8] HOU M M, REN L P, FAN H H, et al. Overview of the quality control of chondroitin sulfate. Chin Pharm J(中国药学杂志), 2016, 51(12):962-966.
[9] WS-10001-(HD-0892)-2002. National Drug Standards(Volumn 9) (国家药品标准第九册),2002:294-295.
[10] SONG Y J, REN L P, FAN H H. Determination of molecular weight and its distribution of chondroitin sulfate sodium . Chin New Drug J(中国新药杂志), 2011, 20(18):1795-1797.
[11] Ch.P(2015). Vol Ⅳ(中国药典 2015 年版. 四部). 2015:167-168.
[12] REN L P, YU H Z, SONG Y J, et al. Study on preparation and standardization of reference standard of chondroitin sulfate sodium. Chin Pharm J (中国药学杂志), 2012, 47(3):236-238.
[13] USP 38/NF33. 2015:5970-5973.
[14] USP 39/NF34. 2016:6570-6572.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
海洋试点国家实验室海洋药物与生物制品功能实验室2018年度开放基金海洋多糖的质控方法研究项目资助(LMDBKF201806)
{{custom_fund}}
PDF(4363 KB)
